JP2022164822A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022164822A5 JP2022164822A5 JP2022137773A JP2022137773A JP2022164822A5 JP 2022164822 A5 JP2022164822 A5 JP 2022164822A5 JP 2022137773 A JP2022137773 A JP 2022137773A JP 2022137773 A JP2022137773 A JP 2022137773A JP 2022164822 A5 JP2022164822 A5 JP 2022164822A5
- Authority
- JP
- Japan
- Prior art keywords
- zfn
- nuclease
- seq
- composition
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024017157A JP2024036610A (ja) | 2017-06-16 | 2024-02-07 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762521132P | 2017-06-16 | 2017-06-16 | |
| US62/521,132 | 2017-06-16 | ||
| US201762542052P | 2017-08-07 | 2017-08-07 | |
| US62/542,052 | 2017-08-07 | ||
| US201762573956P | 2017-10-18 | 2017-10-18 | |
| US62/573,956 | 2017-10-18 | ||
| PCT/US2018/037844 WO2018232296A1 (en) | 2017-06-16 | 2018-06-15 | Targeted disruption of t cell and/or hla receptors |
| JP2019568660A JP7419073B2 (ja) | 2017-06-16 | 2018-06-15 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568660A Division JP7419073B2 (ja) | 2017-06-16 | 2018-06-15 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024017157A Division JP2024036610A (ja) | 2017-06-16 | 2024-02-07 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022164822A JP2022164822A (ja) | 2022-10-27 |
| JP2022164822A5 true JP2022164822A5 (https=) | 2023-09-19 |
| JP7482176B2 JP7482176B2 (ja) | 2024-05-13 |
Family
ID=64656803
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568660A Active JP7419073B2 (ja) | 2017-06-16 | 2018-06-15 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
| JP2022137773A Active JP7482176B2 (ja) | 2017-06-16 | 2022-08-31 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
| JP2024017157A Pending JP2024036610A (ja) | 2017-06-16 | 2024-02-07 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568660A Active JP7419073B2 (ja) | 2017-06-16 | 2018-06-15 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024017157A Pending JP2024036610A (ja) | 2017-06-16 | 2024-02-07 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230295563A1 (https=) |
| EP (1) | EP3638783A4 (https=) |
| JP (3) | JP7419073B2 (https=) |
| KR (1) | KR102708624B1 (https=) |
| CN (1) | CN110997913B (https=) |
| AU (1) | AU2018283310B2 (https=) |
| BR (1) | BR112019026622A2 (https=) |
| CA (1) | CA3066641A1 (https=) |
| IL (1) | IL271298A (https=) |
| SG (1) | SG11201911729SA (https=) |
| WO (1) | WO2018232296A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019015355A2 (pt) * | 2017-01-26 | 2020-05-19 | Sangamo Therapeutics Inc | modificação genética de células b |
| KR20210060533A (ko) * | 2018-09-18 | 2021-05-26 | 상가모 테라퓨틱스, 인코포레이티드 | 프로그램화된 세포 사멸 1 (pd1) 특이적 뉴클레아제 |
| CN116323921A (zh) | 2020-10-28 | 2023-06-23 | 桑格摩生物治疗股份有限公司 | 从人多能干细胞生成cd4+效应t细胞和调节性t细胞 |
| CN113846070B (zh) * | 2021-10-18 | 2023-05-16 | 翌圣生物科技(上海)股份有限公司 | 高活性的mTET2酶突变体、其编码DNA及其应用 |
| CN118325904B (zh) * | 2024-06-17 | 2024-10-01 | 天海元祺生物科技(天津)有限公司 | 高度靶向人类HLA-A基因的sgRNA、其组合物及应用 |
| WO2026083329A1 (en) | 2024-10-18 | 2026-04-23 | Precision Biosciences, Inc. | Methods of nuclease-initiated homology directed repair and replacement and compositions and uses thereof |
| WO2026083328A1 (en) | 2024-10-18 | 2026-04-23 | Precision Biosciences, Inc. | Base editing nucleotide sequences using homology directed repair |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004235395A1 (en) * | 2003-04-29 | 2004-11-11 | Wyeth | Methods for prognosis and treatment of solid tumors |
| AU2009239333A1 (en) * | 2008-04-21 | 2009-10-29 | Danziger Innovations Ltd. | Plant viral expression vectors and use of same for generating genotypic variations in plant genomes |
| KR101551555B1 (ko) * | 2011-03-17 | 2015-09-08 | 밀테니 비오텍 게앰베하 | Tcr 알파/베타가 고갈된 세포 제제 |
| WO2012127464A2 (en) * | 2011-03-23 | 2012-09-27 | Gavish-Galilee Bio Applications Ltd | Constitutively activated t cells for use in adoptive cell therapy |
| CA3131284C (en) * | 2013-08-28 | 2023-09-19 | David Paschon | Compositions for linking dna-binding domains and cleavage domains |
| JP6681837B2 (ja) * | 2014-03-11 | 2020-04-15 | セレクティスＣｅｌｌｅｃｔｉｓ | 同種移植に適合するｔ細胞を作製するための方法 |
| US20170037431A1 (en) * | 2014-05-01 | 2017-02-09 | University Of Washington | In vivo Gene Engineering with Adenoviral Vectors |
| AU2016291778B2 (en) * | 2015-07-13 | 2021-05-06 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| EP3389677B1 (en) * | 2015-12-18 | 2024-06-26 | Sangamo Therapeutics, Inc. | Targeted disruption of the t cell receptor |
| BR112018012235A2 (pt) * | 2015-12-18 | 2018-12-04 | Sangamo Therapeutics Inc | rompimento alvejado do receptor de células de mhc |
| AU2018313167A1 (en) * | 2017-08-08 | 2020-02-27 | Sangamo Therapeutics, Inc. | Chimeric antigen receptor mediated cell targeting |
| CA3089587A1 (en) * | 2018-02-08 | 2019-08-15 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
-
2018
- 2018-06-15 CA CA3066641A patent/CA3066641A1/en active Pending
- 2018-06-15 SG SG11201911729SA patent/SG11201911729SA/en unknown
- 2018-06-15 BR BR112019026622-4A patent/BR112019026622A2/pt not_active IP Right Cessation
- 2018-06-15 WO PCT/US2018/037844 patent/WO2018232296A1/en not_active Ceased
- 2018-06-15 CN CN201880052991.4A patent/CN110997913B/zh active Active
- 2018-06-15 KR KR1020207000964A patent/KR102708624B1/ko active Active
- 2018-06-15 EP EP18818351.1A patent/EP3638783A4/en active Pending
- 2018-06-15 JP JP2019568660A patent/JP7419073B2/ja active Active
- 2018-06-15 AU AU2018283310A patent/AU2018283310B2/en not_active Expired - Fee Related
-
2019
- 2019-12-10 IL IL271298A patent/IL271298A/en unknown
-
2022
- 2022-08-31 JP JP2022137773A patent/JP7482176B2/ja active Active
- 2022-10-21 US US17/971,071 patent/US20230295563A1/en active Pending
-
2024
- 2024-02-07 JP JP2024017157A patent/JP2024036610A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022164822A5 (https=) | ||
| JP2022137018A5 (https=) | ||
| JP2023538891A5 (https=) | ||
| JP2023506765A5 (https=) | ||
| JP2005514063A5 (https=) | ||
| JP2024170524A5 (https=) | ||
| JP2005514030A5 (https=) | ||
| JP2022503959A5 (https=) | ||
| JP2021524270A5 (https=) | ||
| JP2006515749A5 (https=) | ||
| JP2018519296A5 (https=) | ||
| CN106232813B (zh) | 预防减蛋综合征(eds)的疫苗 | |
| WO2005044859A3 (en) | Cd20 antibodies with increased fc receptor binding affinity and effector function | |
| IL274323B1 (en) | Genetic modification of the inducible SH2 cytokine-containing protein gene | |
| JP2013507970A5 (https=) | ||
| JP2024503685A5 (https=) | ||
| JP2015524413A5 (https=) | ||
| JP2019506175A5 (https=) | ||
| JP2023171909A5 (https=) | ||
| JP2024520868A5 (https=) | ||
| JP2014504297A5 (https=) | ||
| CA2474801A1 (en) | Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity | |
| HRP20130022T1 (hr) | Fuzijski proteini koji sadrže antigene ny-eso-1 i lage-1 za odbacivanje tumora | |
| JP2015511599A5 (https=) | ||
| JP2016503434A5 (https=) |